Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
IQ Real Return ETF stock logo
CPI
IQ Real Return ETF
$25.60
0.0%
$25.60
$24.07
$25.80
$7.68M0.271,842 shs500 shs
FIG
Simplify Macro Strategy ETF
$23.83
+1.4%
$23.35
$18.41
$23.83
$10.13M0.454,190 shs6,842 shs
HFGM
Unlimited HFGM Global Macro ETF
$26.85
+1.1%
$26.34
$25.15
$28.10
$17.72MN/A16,979 shs9,172 shs
MAP Pharmaceuticals Inc. stock logo
MAPP
MAP Pharmaceuticals
$24.62
+0.2%
$0.00
$0.00
$0.00
N/AN/AN/AN/A
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
IQ Real Return ETF stock logo
CPI
IQ Real Return ETF
0.00%0.00%0.00%0.00%0.00%
FIG
Simplify Macro Strategy ETF
0.00%0.00%0.00%+15.15%+13.45%
HFGM
Unlimited HFGM Global Macro ETF
+1.13%-0.11%+1.82%+2,684,999,900.00%+2,684,999,900.00%
MAP Pharmaceuticals Inc. stock logo
MAPP
MAP Pharmaceuticals
+0.17%+1.65%+3.17%+9.63%+10.31%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
IQ Real Return ETF stock logo
CPI
IQ Real Return ETF
N/AN/AN/AN/AN/AN/AN/AN/A
FIG
Simplify Macro Strategy ETF
N/AN/AN/AN/AN/AN/AN/AN/A
HFGM
Unlimited HFGM Global Macro ETF
N/AN/AN/AN/AN/AN/AN/AN/A
MAP Pharmaceuticals Inc. stock logo
MAPP
MAP Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
IQ Real Return ETF stock logo
CPI
IQ Real Return ETF
0.00
N/AN/AN/A
FIG
Simplify Macro Strategy ETF
2.50
Moderate Buy$23.83N/A
HFGM
Unlimited HFGM Global Macro ETF
0.00
N/AN/AN/A
MAP Pharmaceuticals Inc. stock logo
MAPP
MAP Pharmaceuticals
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
IQ Real Return ETF stock logo
CPI
IQ Real Return ETF
N/AN/AN/AN/AN/AN/A
FIG
Simplify Macro Strategy ETF
N/AN/AN/AN/AN/AN/A
HFGM
Unlimited HFGM Global Macro ETF
N/AN/AN/AN/AN/AN/A
MAP Pharmaceuticals Inc. stock logo
MAPP
MAP Pharmaceuticals
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
IQ Real Return ETF stock logo
CPI
IQ Real Return ETF
N/AN/A18.48N/AN/AN/AN/AN/A
FIG
Simplify Macro Strategy ETF
N/AN/A21.15N/AN/AN/AN/AN/A
HFGM
Unlimited HFGM Global Macro ETF
N/AN/A0.00N/AN/AN/AN/AN/A
MAP Pharmaceuticals Inc. stock logo
MAPP
MAP Pharmaceuticals
N/AN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
IQ Real Return ETF stock logo
CPI
IQ Real Return ETF
$0.833.24%N/AN/AN/A
FIG
Simplify Macro Strategy ETF
$0.702.94%N/AN/AN/A
HFGM
Unlimited HFGM Global Macro ETF
N/AN/AN/AN/AN/A
MAP Pharmaceuticals Inc. stock logo
MAPP
MAP Pharmaceuticals
N/A2.40%N/AN/AN/A
CompanyEmployeesShares OutstandingFree FloatOptionable
IQ Real Return ETF stock logo
CPI
IQ Real Return ETF
N/A300,000N/ANot Optionable
FIG
Simplify Macro Strategy ETF
N/A425,001N/ANot Optionable
HFGM
Unlimited HFGM Global Macro ETF
N/A660,000N/AN/A
MAP Pharmaceuticals Inc. stock logo
MAPP
MAP Pharmaceuticals
N/AN/AN/ANot Optionable

Recent News About These Companies

Harbor Multi-Asset Explorer ETF Q1 2025 Commentary

Media Sentiment Over Time

Top Headlines

View All Headlines
IQ Real Return ETF stock logo

IQ Real Return ETF NYSEARCA:CPI

$25.60 -0.01 (-0.04%)
As of 12/12/2023

CPI Inflation Hedged ETF seeks investment results, which correspond to the price and yield performance of the IQ CPI Inflation Hedged Index. The Index seeks to provide a hedge against the United States inflation rate by providing a real return or a return above the rate of inflation, as represented by the Consumer Price Index, which is published by the Bureau of Labor Statistics and is a measure of the average change in prices over time of goods and services purchased by households.

Simplify Macro Strategy ETF NYSEARCA:FIG

$23.82 +0.33 (+1.38%)
Closing price 05/23/2025
Extended Trading
$23.82 0.00 (0.00%)
As of 05/23/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

The Simplify Macro Strategy ETF (FIG) is an exchange-traded fund that mostly invests in target outcome asset allocation. The fund is an actively managed fund-of-funds that seeks to provide absolute returns. The fund uses a macro strategy to build a risk-balanced, multi-asset portfolio. FIG was launched on May 16, 2022 and is managed by Simplify.

Unlimited HFGM Global Macro ETF NYSEARCA:HFGM

$26.85 +0.30 (+1.13%)
As of 07/3/2025 05:00 PM Eastern

The Tidal ETF Trust - Unlimited Hfgm Global Macro Return Tracker ETF (HFGM) is an exchange-traded fund that trades on the NYSEARCA exchange in the United States.

MAP Pharmaceuticals stock logo

MAP Pharmaceuticals NASDAQ:MAPP

MAP Pharmaceuticals, Inc., incorporated on July 3, 2003, is a development-stage company. As of December 31, 2011, the Company was focusing to advance its product candidate, LEVADEX (MAP0004) orally inhaled migraine therapy, which is an orally inhaled version of dihydroergotamine mesylate (DHE), for the acute treatment of migraine. The Company had completed clinical development for LEVADEX in 2011 and submitted its New Drug Application (NDA) to the United States Food and Drug Administration (FDA). LEVADEX is at-home therapy in development that patients self-administer using its hand-held TEMPO inhaler. Effective March 1, 2013, Allergen Inc acquired the entire share capital of MAP Pharmaceuticals Inc.